Australia

Immutep

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Immutep Announces United States Patent Grant for IMP701 Antibody

Lead Product(s): IMP701,Spartalizumab

Therapeutic Area: Oncology Product Name: LAG525

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 14, 2020

Details:

This new United States patent is directed to embodiments of LAG525, a humanised form of Immutep’s IMP701 antibody which is out-licensed to Novartis AG.

Immutep

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Immutep Completes Recruitment for Part A of Phase II TACTI-002 Study

Lead Product(s): Eftilagimod Alpha,Pembrolizumab

Therapeutic Area: Oncology Product Name: IMP321

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Merck & Co. Inc.

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 29, 2020

Details:

TACTI-002 is being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA and is evaluating the combination of Immutep’s lead product candidate, eftilagimod alpha (“efti” or “IMP321”) with MSD’s KEYTRUDA® (pembrolizumab).

Kazia Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Kazia Presents Further Paxalisib and Cantrixil Data at AACR, Reinforcing Positive Efficacy Signals for both Drugs

Lead Product(s): Paxalisib

Therapeutic Area: Oncology Product Name: GDC-0084

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 22, 2020

Details:

Previous paxalisib data presented at ASCO was based on Stage 1 (n=9) of the ongoing phase II study in glioblastoma. This interim analysis at AACR includes all patients in the study (n=30), and therefore provides a more robust and substantial data set.

Immutep

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Immutep Announces Results From INSIGHT-004 Phase I study Of EFTI In Combo With Avelumabto Treat Solid Cancers

Lead Product(s): Eftilagimod Alpha,Pembrolizumab

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Merck & Co. Inc.

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 01, 2020

Details:

First complete response reported in 2nd line head and neck squamous cell carcinoma (HNSCC), and Improved Overall Response Rate and Progression free survival is reported TACTI-002 is evaluating the combination eftilagimod alpha pembrolizumab second line HNSCC.

Kazia Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Kazia Presents Interim Paxalisib Phase II Data at ASCO Showing Positive Overall Survival Signal

Lead Product(s): Paxalisib

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 01, 2020

Details:

Analysis of Stage 1 of the study (n=9) shows median overall survival (OS) of 17.7 months. This compares very favourably with temozolomide, the existing standard of care, which has a reported median OS of 12.7 months in this patient population.

Immutep

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Immutep Reports Positive Phase II TACTI-002 Data

Lead Product(s): Eftilagimod Alpha,Pembrolizumab

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 28, 2020

Details:

Results from stage 1 demonstrate the benefits for NSCLC patients in receiving efti in combination with pembrolizumab.

Immutep

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Immutep TACTI-002 Data Presentation at the AACR Virtual Annual Meeting 2020

Lead Product(s): Eftilagimod Alpha,Pembrolizumab

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 14, 2020

Details:

The data in this presentation relates to Immutep’s lead product candidate, eftilagimod alpha, as part of a combination treatment with pembrolizumab, an anti-PD-1 therapy.

Kazia Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Kazia's Paxalisib Shows Positive Overall Survival Signal in Phase II Glioblastoma Study

Lead Product(s): Paxalisib

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 07, 2020

Details:

Interim analysis of Part showed median overall survival of 17.7 months, representing a clinically meaningful extension of life when compared to the 12.7 months of temozolomide.

Immutep

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Immutep to Present TACTI-002 Interim Data at German Cancer Congress

Lead Product(s): Eftilagimod Alpha

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 04, 2020

Details:

The data relates to use of the company’s lead product candidate eftilagimod alpha, as part of a combination treatment with pembrolizumab.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Immutep

Immutep Announces United States Patent Grant for IMP701 Antibody

Immutep

Immutep Completes Recruitment for Part A of Phase II TACTI-002 Study

Kazia Therapeutics

Kazia Presents Further Paxalisib and Cantrixil Data at AACR, Reinforcing Positive Efficacy Signals for both Drugs

Immutep

Immutep Announces Results From INSIGHT-004 Phase I study Of EFTI In Combo With Avelumabto Treat Solid Cancers

Kazia Therapeutics

Kazia Presents Interim Paxalisib Phase II Data at ASCO Showing Positive Overall Survival Signal

Immutep

Immutep Reports Positive Phase II TACTI-002 Data

Immutep

Immutep TACTI-002 Data Presentation at the AACR Virtual Annual Meeting 2020

Kazia Therapeutics

Kazia's Paxalisib Shows Positive Overall Survival Signal in Phase II Glioblastoma Study

Immutep

Immutep to Present TACTI-002 Interim Data at German Cancer Congress